menu

Advancing Global Care with Emerging BTKi in Relapsed/Refractory CLL: Connecting Hematology Leaders to Worldwide Learners

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Advancing Global Care with Emerging BTKi in Relapsed/Refractory CLL: Connecting Hematology Leaders to Worldwide Learners

0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    The validation of targeted agent classes, driven by the emergence of BTK inhibitors as a highly effective therapeutic tool, has transformed the medical management of CLL/SLL and led to similar advances for other B-cell malignancies. Although this transformation has substantially improved outcomes, challenges remain and are centered on the problem of devising truly individualized sequential care in the relapsed/refractory disease setting, where outcomes to date have not improved as dramatically as those for newly diagnosed/treatment-naïve disease. Therapeutic intolerance and challenges involving adverse event management, BTK inhibitor resistance, and double-refractory status contribute to therapy interruption or discontinuation and abrogate clinical benefits associated with continued BTK inhibitor therapy, leading to subsequent care that is suboptimal due to a dearth of effective treatment options.

    The educational activity, featuring an expert panel discussion comprised of 1 US and 2 international faculty thought leaders, will provide an evaluation of the most recent clinical data and expert insights on the current and emerging evidence supporting the clinical utility of BTK inhibitors in relapsed/refractory CLL/SLL.

  • Disclosure of Relevant Financial Relationships

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an  activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Anthony Mato, MD, MSCE, reported a financial interest/relationship or affiliation in the form of Consulting or advisory role: AbbVie, Acerta Pharma/Astra Zeneca, Adaptive Biotechnologies, Celgene Corporation, DTRM Biopharma Co. Ltd., Genentech, Inc., Genmab A/S, Johnson & Johnson Services Inc., Nurix Therapeutics, Inc., Octapharma Plasma, Inc., Pharmacyclics, Inc., Sunesis Pharmaceuticals, Inc., TG Therapeutics, Inc. and Verastem Inc. Grant/Research support: AbbVie, Acerta Pharma/AstraZeneca, Adaptive Biotechnologies, DTRM Biopharma Co. Ltd., Genentech, Inc., Genmab A/S, Johnson & Johnson Services, Inc., Loxo Oncology, Inc., Nurix Therapeutics, Inc., Octapharma Plasma, Inc., Pharmacyclics, Inc., Regeneron Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc., TG Therapeutics, Inc. Data and safety monitoring board: AbbVie, Acerta Pharma/AstraZeneca, Adaptive Biotechnologies, Celgene Corporation, DTRM Biopharma Co. Ltd., Genentech, Inc., Genmab A/S, Johnson & Johnson Services, Inc., Nurix Therapeutics, Inc., Octapharma Plasma, Inc., Pharmacyclics, Inc., TG Therapeutics, Inc Sunesis Pharmaceuticals, Inc. and Verastem Inc.

    Toby A. Eyre, MD, MBChB, reported a financial interest/relationship or affiliation in the form of Consultant: AbbVie, AstraZeneca, BeiGene, Gilead Sciences, Inc., Incyte, Janssen, Kite Pharma, Lilly, Loxo Oncology, Inc., Roche. Speaker: AbbVie, AstraZeneca, BeiGene, Gilead, Incyte, Janssen, Kite Pharma, Lilly, Loxo Oncology, Inc., Roche. Research grant; AstraZeneca and BeiGene.

    Tahla Munir, PhD, reported a financial interest/relationship or affiliation in the form of Advisor: Alexion Pharmaceuticals, AstraZeneca, BeiGene, Janssen, Roche, and Sobi. Speaker: AbbVie, Alexion Pharmaceuticals, AstraZeneca, Janssen, and Sobi.

    The directors, planners, managers, and reviewers reported the  following financial relationships they have with any ineligible  company of any amount during the past 24 months:  Linda  Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; Melissa Duffy, PA-C; and Dee Morgillo, MEd, MT(ASCP), CHCP, hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Target Audience

    This activity is intended for US and global academic and community-based pathologists, advanced practitioners, and hematology/oncology nurses who are part of the interprofessional team responsible for the therapeutic management of patients with relapsed/refractory CLL/SLL.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Discuss the differences between US and European treatment and guideline recommendations for relapsed/refractory CLL/SLL
    • Explain the mechanism of action, efficacy, and safety differences between covalent and noncovalent BTK inhibitors, including implications related to therapeutic intolerance and resistance
    • Create potential treatment plans for relapsed/refractory CLL/SLL that include emerging BTK inhibitors based on prognostic factors, safety, and selectivity differences
  • Accreditation and Credit Designation Statements

    Accreditation Statement

     

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

     

     

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

     

     

     

     


    Credit Designation for Physicians

    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits.  Approval is valid until March 29, 2024. PAs should only claim credit commensurate with the extent of their participation.

     

     

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hour of continuing pharmacy education JA4008106-0000-23-003-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Credit Designation for Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 0.5 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program

     

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by AXIS Medical Education.

  • Commercial Support

    This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

  • Method of Participation and Request for Credit

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    The validation of targeted agent classes, driven by the emergence of BTK inhibitors as a highly effective therapeutic tool, has transformed the medical management of CLL/SLL and led to similar advances for other B-cell malignancies. Although this transformation has substantially improved outcomes, challenges remain and are centered on the problem of devising truly individualized sequential care in the relapsed/refractory disease setting, where outcomes to date have not improved as dramatically as those for newly diagnosed/treatment-naïve disease. Therapeutic intolerance and challenges involving adverse event management, BTK inhibitor resistance, and double-refractory status contribute to therapy interruption or discontinuation and abrogate clinical benefits associated with continued BTK inhibitor therapy, leading to subsequent care that is suboptimal due to a dearth of effective treatment options.

    The educational activity, featuring an expert panel discussion comprised of 1 US and 2 international faculty thought leaders, will provide an evaluation of the most recent clinical data and expert insights on the current and emerging evidence supporting the clinical utility of BTK inhibitors in relapsed/refractory CLL/SLL.

  • Disclosure of Relevant Financial Relationships

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an  activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Anthony Mato, MD, MSCE, reported a financial interest/relationship or affiliation in the form of Consulting or advisory role: AbbVie, Acerta Pharma/Astra Zeneca, Adaptive Biotechnologies, Celgene Corporation, DTRM Biopharma Co. Ltd., Genentech, Inc., Genmab A/S, Johnson & Johnson Services Inc., Nurix Therapeutics, Inc., Octapharma Plasma, Inc., Pharmacyclics, Inc., Sunesis Pharmaceuticals, Inc., TG Therapeutics, Inc. and Verastem Inc. Grant/Research support: AbbVie, Acerta Pharma/AstraZeneca, Adaptive Biotechnologies, DTRM Biopharma Co. Ltd., Genentech, Inc., Genmab A/S, Johnson & Johnson Services, Inc., Loxo Oncology, Inc., Nurix Therapeutics, Inc., Octapharma Plasma, Inc., Pharmacyclics, Inc., Regeneron Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc., TG Therapeutics, Inc. Data and safety monitoring board: AbbVie, Acerta Pharma/AstraZeneca, Adaptive Biotechnologies, Celgene Corporation, DTRM Biopharma Co. Ltd., Genentech, Inc., Genmab A/S, Johnson & Johnson Services, Inc., Nurix Therapeutics, Inc., Octapharma Plasma, Inc., Pharmacyclics, Inc., TG Therapeutics, Inc Sunesis Pharmaceuticals, Inc. and Verastem Inc.

    Toby A. Eyre, MD, MBChB, reported a financial interest/relationship or affiliation in the form of Consultant: AbbVie, AstraZeneca, BeiGene, Gilead Sciences, Inc., Incyte, Janssen, Kite Pharma, Lilly, Loxo Oncology, Inc., Roche. Speaker: AbbVie, AstraZeneca, BeiGene, Gilead, Incyte, Janssen, Kite Pharma, Lilly, Loxo Oncology, Inc., Roche. Research grant; AstraZeneca and BeiGene.

    Tahla Munir, PhD, reported a financial interest/relationship or affiliation in the form of Advisor: Alexion Pharmaceuticals, AstraZeneca, BeiGene, Janssen, Roche, and Sobi. Speaker: AbbVie, Alexion Pharmaceuticals, AstraZeneca, Janssen, and Sobi.

    The directors, planners, managers, and reviewers reported the  following financial relationships they have with any ineligible  company of any amount during the past 24 months:  Linda  Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; Melissa Duffy, PA-C; and Dee Morgillo, MEd, MT(ASCP), CHCP, hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Target Audience

    This activity is intended for US and global academic and community-based pathologists, advanced practitioners, and hematology/oncology nurses who are part of the interprofessional team responsible for the therapeutic management of patients with relapsed/refractory CLL/SLL.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Discuss the differences between US and European treatment and guideline recommendations for relapsed/refractory CLL/SLL
    • Explain the mechanism of action, efficacy, and safety differences between covalent and noncovalent BTK inhibitors, including implications related to therapeutic intolerance and resistance
    • Create potential treatment plans for relapsed/refractory CLL/SLL that include emerging BTK inhibitors based on prognostic factors, safety, and selectivity differences
  • Accreditation and Credit Designation Statements

    Accreditation Statement

     

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

     

     

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

     

     

     

     


    Credit Designation for Physicians

    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits.  Approval is valid until March 29, 2024. PAs should only claim credit commensurate with the extent of their participation.

     

     

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hour of continuing pharmacy education JA4008106-0000-23-003-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Credit Designation for Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 0.5 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program

     

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by AXIS Medical Education.

  • Commercial Support

    This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

  • Method of Participation and Request for Credit

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule25 Feb 2024